Entera Bio Ltd. (NASDAQ:ENTX) has appointed seasoned pharmaceutical executive Geno J. Germano as Chairman of the Board, effective February 4, 2026, as the company approaches several key clinical milestones. He succeeds Gerald Lieberman, who is stepping down from the role.
The leadership change comes as Entera prepares to move two oral parathyroid hormone (PTH) peptide programs into clinical development this year, including a Phase 3 registrational trial of EB613 for osteoporosis and a first-in-human study of its long-acting oral PTH candidate for hypoparathyroidism.
“Entera’s lead clinical asset, EB613, has the potential to fundamentally change how osteoporosis is treated,” said Mr. Germano. “While anabolic therapies are well established as highly effective, their use has largely been limited by the burden of injections. An oral anabolic therapy could move bone-building treatment earlier in the treatment paradigm and into frontline use for a much broader patient population. Combined with Entera’s plans for hypoparathyroidism and metabolic diseases, I look forward to working with the team as the Company enters this pivotal phase of development and execution.”
Chief Executive Officer Miranda Toledano thanked the outgoing chairman and welcomed Germano to the role.
“I would like to thank Jerry immensely for his contributions during his tenure on the board,” said Toledano. “We are truly honored to welcome Geno as Chairman. The last three years have set the foundation for Entera’s highly differentiated oral peptide pipeline, N-Tab® platform, regulatory alignment and transition to late-stage clinical testing. Geno’s decades of global biopharmaceutical leadership experience and proven ability to scale highly differentiated therapeutic platforms through late-stage development and toward commercialization will be a critical asset to Entera. We are looking forward to working together with Geno’s as we advance Entera to its next phase,” she added.
Germano brings more than 30 years of experience in global pharmaceutical development and commercialization. During his tenure at Pfizer, he served as Group President of the company’s Global Innovative Pharmaceutical Business, overseeing a portfolio valued at approximately $14 billion and guiding late-stage pipeline strategy. He also held senior roles leading Pfizer’s Specialty Care and Oncology divisions and previously co-chaired the company’s Portfolio Strategy and Investment Committee.
Beyond Pfizer, Germano has served on the boards of several biotechnology companies, including Precision Biosciences and, in recent years, Sage Therapeutics, Orbital Therapeutics, Bioverativ and The Medicines Company.
More about Entera Bio
Entera Bio is a clinical-stage biotechnology company focused on developing oral peptide and protein replacement therapies using its proprietary N-Tab® technology platform. Its pipeline includes oral PTH(1-34) candidates for osteoporosis and hypoparathyroidism, as well as oral peptide programs targeting GLP-1, GLP-2 and oxyntomodulin for metabolic and gastrointestinal disorders. The company aims to replace injectable therapies with convenient oral alternatives for patients with significant unmet medical needs.